Decision-making factors for the long-term topical treatment of mild-to-moderate plaque psoriasis: TEPPSO, a case-vignette study on clinical practice

• Published in: Annales de dermatologie et de vénéréologie Vol. 150; no. 1; pp. 28 - 34
• Main Authors: Quiles-Tsimaratos, N., Paul, C., De La Brassinne, M., Telle-Sauvant, H., Corgibet-Escallier, F., Tanasescu, S., Roux, B., Girardot-Seguin, S., Duval-Modeste, A.-B.
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.03.2023
• Subjects: Administration, Topical; Adrenal Cortex Hormones - administration & dosage; Adrenal Cortex Hormones - therapeutic use; Case-vignettes; Clinical Decision-Making; Cross-Sectional Studies; General Practitioners; Plaque psoriasis; Psoriasis - therapy; Quality of Life; Topical treatment; Treatment Outcome; Vitamin D - administration & dosage; Vitamin D - therapeutic use; Case-vignettes; Topical treatment; Plaque psoriasis
• ISSN: 0151-9638
• DOI: 10.1016/j.annder.2022.05.003

Topical maintenance therapy strategy with regard to patients with mild-to-moderate plaque psoriasis (PP) continues to be heterogeneous and insufficiently investigated in real-life clinical practice. The objective of this study was to describe the initiation of long-term maintenance treatment and to identify clinical parameters influencing the therapeutic decision. TEPPSO was a French and Belgian multicentre cross-sectional study based on completion of questionnaires and assessment of credible clinical scenarios of mild-to-moderate PP by physicians using the validated case-vignette method. Maintenance therapy was recommended by dermatologists (Ds) and by general practitioners (GPs) in 79.1% and 76.8% of cases, respectively. GPs recommended the use of a fixed-dose combination of corticosteroid and vitamin D analogues in only 14.8% of cases, whereas this therapy was recommended by French and Belgian Ds in 54.8% and 39.8% of cases, respectively. In a multivariate analysis, significant determinants of the therapeutic decision were skin lesions impacting quality of life (OR 1.9 [95% CI: 1.1; 3.2] P=0.01) for Ds, and patient corticophobia (OR 1.7 [95% CI: 1.1; 2.7] P=0.03) or the presence of skin pruritus (OR 1.8 [95% CI: 1.2; 1.8] P=0.004) for GPs, respectively. Maintenance treatment with topical agents in patients with mild-to-moderate PP was considered in more than two thirds of cases. Heterogeneity in the choice of topical agents was evidenced particularly between Ds and GPs. Our study is the first to identify significant clinical determinants affecting the therapeutic decision. Updated and validated clinical practice guidelines are needed to ensure uniform therapeutic choices.